PCSK9 Forum
Click here to invite colleagues
to join the Forum for FREE
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
Special review
Do PCSK9 inhibitors have long-term benefits?

In this specially commissioned review Professor Chris J. Packard discusses the promise of personalized, disease-orientated treatment goals based on the profound LDL-cholesterol lowering effects of PCSK9 inhibitors in people at high risk of premature death from cardiovascular disease.

Legacy effects: A proposed strategy

Professor Chris J. Packard

Professor Chris J. Packard
College of Medical, Veterinary and Life Sciences
University of Glasgow

Read Dr Packard’s review »

Forward to colleagues »
Legacy effects: A proposed strategy
Related articles

Does the mechanism of lowering LDL cholesterol matter?
Insights from recent Mendelian Randomization studies. Meta-analyses of numerous randomized trials have demonstrated that lowering LDL-cholesterol by inhibiting HMG-CoA reductase with a statin reduces the risk of major cardiovascular events by approximately 20% for each mmol/L lower LDL cholesterol.
Read more »

Lowering LDL-C: at what level would this impact the benefit vs. risk ratio?
Potent inhibitors of PCSK9 have the capacity to reduce plasma low-density lipoprotein cholesterol to unprecedentedly low levels, especially if combined with statins.
Read more »

Managing LDL-C: can we redefine targets?
Despite all the consternation and debate about the US versus European guidelines for lipid management, it is important to remember that there are a number of important consistencies.
Read more »

Lowering LDL: how low and for how long?
Treatment to reduce low-density lipoprotein cholesterol should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks.
Read more »
Click here to invite colleagues to join FREE
Why are new treatments needed?

Inhibition of PCSK9 offers the real possibility of improved management of high-risk patients.

Read the full answer and other questions on the PCSK9 Forum »
Free e-book
Understanding PCSK9 inhibition
For healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Available free.

Register and read online »    Download now »
PCSK9 Inhibition Handbook
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.